Treatment of chronic granulocytic leukemia with melphalan
T Hauch, G Logue, J Laszlo, E Cox and W Rundles
Thirty-three patients with newly diagnosed chronic granulocytic leukemia
(CGL) were treated with melphalan between 1968 and 1976. Within 3 mo of
beginning therapy subjective and objective disease parameters improved.
Disease control was easily maintained with this agent until hematologic
exacerbation occurred. The median duration of disease control was 25.3 mo,
and the median duration of survival was 28.6 mo. Serious side effects were
not produced. Thus melphalan appears to be another agent that may be used
to control the manifestations of CGL prior to hematologic exacerbation.
Volume 51,
Issue 4,
pp. 571-577,
04/01/1978
Copyright © 1978 by The American Society of Hematology
